Abstract
We have investigated the cytotoxicity in Saccharomyces cerevisiae of the novel antitumor agent 3-bromopyruvate (3-BP). 3-BP enters the yeast cells through the lactate/pyruvate H+ symporter Jen1p and inhibits cell growth at minimal inhibitory concentration of 1.8 mM when grown on non-glucose conditions. It is not submitted to the efflux pumps conferring Pleiotropic Drug Resistance in yeast. Yeast growth is more sensitive to 3-BP than Gleevec (Imatinib methanesulfonate) which in contrast to 3-BP is submitted to the PDR network of efflux pumps. The sensitivity of yeast to 3-BP is increased considerably by mutations or chemical treatment by buthionine sulfoximine that decrease the intracellular concentration of glutathione.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Balzi E, Chen W, Ulaszewski S, Capieaux E, Goffeau A (1987) The multidrug resistance gene PDR1 from Saccharomyces cerevisiae. J Biol Chem 262(35):16871–16879
Barnard JP, Reynafarje B, Pedersen PL (1993) Glucose Catabolism in African Trypanosomes. J Biol Chem 268(5):3661
Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya MV et al (2009) Efflux-mediated antifungal drug resistance. Clin Microbiol Rev 22(2):291–321
Cardenas ME, Cruz MC, Del Poeta M, Chung N, Perfect JR, Heitman J (1999) Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin Microbiol Rev 12(4):583–611
Casal M, Paiva S, Andrade RP, Gancedo C, Leão C (1999) The lactate-proton symport of Saccharomyces cerevisiae is encoded by JEN1. J Bacteriol 181(8):2620–2623
Cassio F, Leão C, van Uden N (1987) Transport of lactate and other short-chain monocarboxylates in the yeast Saccharomyces cerevisiae. Appl Environ Microbiol 53(3):509–513
Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A et al (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8(1):935–942
De Hertogh B, Carvajal E, Talla E, Dujon B, Baret P, Goffeau A (2002) Phylogenetic classification of transporters and other membrane proteins from Saccharomyces cerevisiae. Funct Integr Genom 2(4–5):154–170
De Lima LPO, De Faria TRB, Portes JA, Pinho NZ, De Souza TG, De Souza, W et al (2011) 3-BrPA And FeHP(SO4). Affect the growth of Toxoplasma gondii and induce the conversion of tachyzoites in bradyzoites during interaction with LLC-MK2. Laboratorio de Tecnologia em Bioquimica e Microscopia, UEZO, Rio de Janeiro, RJ.http://www.csbmm2011.com.br/arearestrita/arquivos/16809.pdf. Accessed 2011.
Decottignies A, Grant MA, Nichols JW, de Wet H, McIntosh DB, Goffeau A (1988) ATPase and multidrug transport activities of the overexpressed yeast ABC protein Yor1p. J Biol Chem 273(20):12612–12622
Decottignies A, Rogers B, Kolaczkowski M, Carvajal E, Balzi E, Conseil G et al (2001) The pleiotropic drug ABC transporters from Saccharomyces cerevisiae. In: Microbial multidrug efflux. (pp.157-176). Horizon Scientific Press, Wymondham, UK
Dusre L, Mimnaugh G, Myers CE, Sinha BK (1989) Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Cancer Res 49(1):511–515
Dylag M, Pruchnik H, Pruchnik F, Majkowska-Skrobek G, Ułaszewski S (2010) Antifungal activity of organotin compounds with functionalized carboxylates evaluated by the microdilution bioassay in vitro. Med Mycol 48(2):373–383
Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82(1):70–77
Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58(1):1137–1171
Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL (2002) Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62(1):3909–3913
Goffeau A, Barrell BG, Bussey H, Davis RW, Dujon B, Feldmann H et al (1996) Life with 6000 Genes. Science, 274(5287), 546 + 563-567
Gonzalez B, François J, Renaud M (1997) A rapid and reliable method for metabolite extraction in yeast using boiling buffered ethanol. Yeast 13(1):1347–1355
Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multudrug transporter. Annu Rev Biochem 62(1):385–427
Hoepfl J, Miething C, Grundler R, Gotze KS, Peschel C, Duyster J (2002) Effects of imatinib on bone marrow engraftment in syngenic mice. Leukemia 16(9):1584
Izumi H, Takahashi M, Yramoto H, Nakayama Y, Oyama T, Wang KY et al (2011) Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer. Canc Sci 102(5):1007–1013
Kaiser C, Michaelis S, Mitchel AA (1994) Cold Spring Harbor laboratory course manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, Methods in yeast genetics
Karathia H, Vilaprinyo E, Sorribas A, Alves R (2011) Saccharomyces cerevisiae as a model organism: a comparative study. PLoS One 6(2):1–17
Ko YH, Pedersen PL, Geschwind JF (2001) Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173(1):83–91
Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS et al (2004) Advanced cancers: eradication in all cases using 3- bromopyruvate therapy to deplete ATP. Biochem Biophys Res Comm 5(1):269–275
Kolaczkowski M, Kolaczowska A, Luczynski J, Witek S, Goffeau A (1998) In vivo characterization of the drug resistance profile of the major ABC transporters and other components of the yeast pleiotropic drug resistance network. Microb Drug Res 4(3):143–158
Kurtz JE, Dufour P, Bergerat JP, Exinger F (2005) Saccharomyces Cerevisiae as a genetic model in anticancer therapy. Current Pharmacogenomics 3(1):1–7
Mager W, Winderickx J (2005) Yeast as a model for medical and medicinal research. Trends Pharmacol Sci 26(5):265–273
Makuc J, Paiva S, Schauen M, Kramer R, Andre B, Casal M et al (2001) The putative monocarboxylate permeases of the yeast Saccharomyces cerevisiae do not transport monocarboxylic acids across the plasma membrane. Yeast 18(12):1131–1143
Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25(1):4777–4786
Mathupala SP, Ko YH, Pedersen PL (2009) Hexokinase-2 bound to mitochondria: cancer’s stygian link to the “Warburg Effect” and a pivotal target for effective therapy. Semin Canc Biol 19(1):17–24
Mathupala SP, Ko YH, Pedersen P (2010) The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta 1797(1):1225–1230
Ohtake Y, Satou A, Yabuuchi S (1990) Isolation and characterization of glutathione biosynthesis-deficient mutants in Saccharomyces cerevisiae. Agric Biol Chem 54(12):3145–3150
Outten CE, Falk RL, Culotta VC (2005) Cellular factors required for protection from hyperoxia toxicity in Saccharomyces cerevisiae. Biochem J 388(1):93–101
Pedersen PL (1978) Tumor mitochondria and the bioenergetics of cancer cells. Progr Exp Tumor Res 22(1):190–274
Pedersen PL (2007) Warburg, me and hexokinase2: multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39(1):211–222
Porporato PE, Dhup S, Dadlich RK, Copetti T, Sonveaux P (2010) Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2(49):1–18
Prasad R, Goffeau A (2012) Yeast ATP-binding cassette transporters conferring multidrug resistance. Annual Review Microbiology, in press
Qin J-Z, Xin H, Nickoloff BJ (2010) 3-bromopyruvate induces necrotic cell death in sensitive melanoma cell lines. Biochem Biophys Res Comm 396(1):495–500
Reihl P, Stolz J (2005) The monocarboxylate transporter homolog Mch5p catalyzes riboflavin (vitamin B2) uptake in Saccharomyces cerevisiae. J Biol Chem 280(48):39809–39817
Reliene R, Schiestl RH (2006) Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice. Carcinogenesis 27(2):240–244
Suter B, Auerbach D, Stagljar J (2006) Yeast-based functional genomics and proteomics technologies: the first 15 years and beyond. Biotechniques 40(1):625–644
Thomas BJ, Rothstein R (1989) Elevated recombination rates in transcriptionally active DNA. Cell 58(1):819–830
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Lis, P., Zarzycki, M., Ko, Y.H. et al. Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae . J Bioenerg Biomembr 44, 155–161 (2012). https://doi.org/10.1007/s10863-012-9421-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10863-012-9421-8